INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,395,804 | -17.1% | 26,796 | +0.8% | 0.00% | -25.0% |
Q2 2023 | $1,684,059 | +9.1% | 26,596 | -6.7% | 0.00% | 0.0% |
Q1 2023 | $1,543,058 | +2.3% | 28,496 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $1,508,008 | +13.8% | 28,496 | +0.1% | 0.00% | +33.3% |
Q3 2022 | $1,325,000 | -18.5% | 28,466 | 0.0% | 0.00% | -25.0% |
Q2 2022 | $1,625,000 | -3.6% | 28,466 | +3.3% | 0.00% | +33.3% |
Q1 2022 | $1,686,000 | +16.9% | 27,546 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $1,442,000 | +41.9% | 27,546 | +1.1% | 0.00% | +50.0% |
Q3 2021 | $1,016,000 | -8.6% | 27,253 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $1,112,000 | +27.2% | 27,253 | +5.8% | 0.00% | 0.0% |
Q1 2021 | $874,000 | +6.6% | 25,768 | -0.0% | 0.00% | 0.0% |
Q4 2020 | $820,000 | +22.9% | 25,778 | -0.8% | 0.00% | 0.0% |
Q3 2020 | $667,000 | +21.1% | 25,988 | +21.2% | 0.00% | +100.0% |
Q2 2020 | $551,000 | +67.0% | 21,448 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $330,000 | -55.2% | 21,448 | 0.0% | 0.00% | -50.0% |
Q4 2019 | $736,000 | +360.0% | 21,448 | 0.0% | 0.00% | – |
Q3 2019 | $160,000 | -42.4% | 21,448 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $278,000 | +10.8% | 21,448 | +4.1% | 0.00% | 0.0% |
Q1 2019 | $251,000 | +6.8% | 20,608 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $235,000 | -47.1% | 20,608 | +0.7% | 0.00% | 0.0% |
Q3 2018 | $444,000 | +22.7% | 20,462 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $362,000 | +0.8% | 20,462 | +19.9% | 0.00% | 0.0% |
Q1 2018 | $359,000 | +52.1% | 17,062 | +4.9% | 0.00% | 0.0% |
Q4 2017 | $236,000 | -3.7% | 16,265 | +5.0% | 0.00% | 0.0% |
Q3 2017 | $245,000 | +27.6% | 15,495 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $192,000 | -23.8% | 15,495 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $252,000 | +7.7% | 15,495 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $234,000 | -0.8% | 15,495 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $236,000 | -58.7% | 15,495 | +5.1% | 0.00% | -50.0% |
Q2 2016 | $572,000 | +50.5% | 14,745 | +7.8% | 0.00% | +100.0% |
Q1 2016 | $380,000 | -37.8% | 13,677 | +20.4% | 0.00% | -50.0% |
Q4 2015 | $611,000 | – | 11,357 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |